• Safety
  • Discontinuation Rates

TRODELVY 200mg

Safety

TRODELVY has a well-characterised safety profile1

In the Phase 3 ASCENT trial:

Phase 3 ASCENT trial
  • No patients in the TRODELVY group discontinued treatment due to treatment-related neutropenia or diarrhoea

REFERENCES:

  1. TRODELVY (sacituzumab govitecan) Summary of Product Characteristics, July 2023.
  2. Rugo H, et al. NPJ Breast Cancer. 2022; 8: 98.doi: 10.1038/s41523-022-00467-1.
  3. Bardia A, et al. N Engl J Med. 2021;384(16):1529–1541.